Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer
| Autor: | Robert S. Witte, Peter A. Beatty, James McGovern, Joan H. Schiller, Tien Hoang, Gary Shapiro, Paul L. Koch, Maria Quisumbing, Anthony Jaslowski, KyungMann Kim |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine Antimetabolites Antineoplastic Cancer Research medicine.medical_specialty Lung Neoplasms Maximum Tolerated Dose medicine.medical_treatment Deoxycytidine Small-cell carcinoma Gastroenterology chemistry.chemical_compound Internal medicine medicine Humans Carcinoma Small Cell Lung cancer Survival rate Aged Chemotherapy Performance status business.industry Middle Aged medicine.disease Gemcitabine Chemotherapy regimen Carboplatin Surgery Survival Rate Treatment Outcome Oncology chemistry Drug Resistance Neoplasm Female Neoplasm Recurrence Local business medicine.drug |
| Zdroj: | Lung Cancer. 42:97-102 |
| ISSN: | 0169-5002 |
| Popis: | Small cell lung cancer (SCLC) is highly sensitive to chemotherapy. Despite a dramatic initial response, however, most patients relapse. Given the activity of gemcitabine in non-small cell lung cancer (NSCLC), and early clinical trials suggesting activity of gemcitabine in chemo-naive SCLC patients, we conducted a phase II study to determine the efficacy and toxicities of gemcitabine in SCLC patients who have failed first-line chemotherapy. Gemcitabine 1250 mg/m2 was given intravenously on days 1 and 8, every 3 weeks. Eligibility criteria included prior treatment with only one chemotherapy regimen and Eastern Cooperative Oncology Group (ECOG) performance status of 0–2. Patients with brain metastases were eligible. Results: Between April 1998 and October 2001, 27 patients were enrolled: 15 patients with sensitive (S) disease (recurred>3 months after first-line chemotherapy) and 12 patients with refractory (R) disease (failed |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect